Currently, there are 51.40M common shares owned by the public and among those 48.60M shares have been available to trade.
The company’s stock has a 5-day price change of 1.19% and -36.01% over the past three months. SYRE shares are trading -1.55% year to date (YTD), with the 12-month market performance up to 2.03% higher. It has a 12-month low price of $20.07 and touched a high of $47.97 over the same period. SYRE has an average intraday trading volume of 608.16K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.24%, -2.25%, and -19.78% respectively.
Institutional ownership of Spyre Therapeutics Inc (NASDAQ: SYRE) shares accounts for 94.95% of the company’s 51.40M shares outstanding.
It has a market capitalization of $1.35B and a beta (3y monthly) value of 2.98. The stock’s trailing 12-month PE ratio is 2.49, while the earnings-per-share (ttm) stands at $9.21. The company has a PEG of 0.04 and a Quick Ratio of 7.32 with the debt-to-equity ratio at 0.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.41% over the week and 6.34% over the month.
Earnings per share for the fiscal year are expected to increase by 91.31%, and 9.48% over the next financial year. EPS should grow at an annualized rate of 56.12% over the next five years, compared to 23.71% over the past 5-year period.
Looking at the support for the SYRE, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on September 04, 2024, with the firm’s price target at $45. Robert W. Baird was of a view on May 02, 2024 that the stock is Outperform, while Wells Fargo gave the stock Overweight rating on March 01, 2024, issuing a price target of $12- $35. BTIG Research on their part issued Buy rating on December 20, 2023.
